Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Operating activities:
Net income	$ 273,760	$ 922,457
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	678,689	724,224
Stock-based compensation	32,271	90,911
Non-cash gain on loan modification	0	(410,320)
Deferred income taxes	52,371	192,315
Foreign currency transaction (gain)/loss	51,867	(34,805)
(Increase) decrease in accounts receivable	(31,966)	46,912
(Increase) decrease in inventories	135,445	(571,275)
(Increase) decrease in refundable income taxes	(23,501)	(154,252)
(Increase) decrease in prepaid expenses and other current assets	(325,147)	(201,100)
(Increase) decrease in other assets	(30,071)	(15,219)
Increase (decrease) in accounts payable & accrued expenses and other noncurrent liabilities	485,710	466,794
Net cash provided by operating activities	1,299,428	1,056,642
Investing activities:
Purchase of property, plant and equipment	(303,290)	(390,778)
Purchase of note and mortgage secured by underlying property	0	(2,000,000)
Payments received on distributor note receivable	56,990	0
Acquisition of lunasin technology agreement	(1,150,000)	0
Payment of life insurance premiums	(259,726)	(259,121)
Net cash used in investing activities	(1,656,026)	(2,649,899)
Financing activities:
Proceeds from revolving line of credit borrowings	1,150,000	0
Principal payments on long-term borrowings	(527,591)	(465,634)
Common stock dividends paid	(252,380)	(250,283)
Proceeds from options and warrants exercised	579	0
Purchase of stock for treasury	(5,364)	(69,386)
Net cash provided by (used in) financing activities	365,244	(785,303)
Effect of exchange rate changes on cash and cash equivalents	(65,495)	105,430
Increase (decrease) in cash and cash equivalents	(56,849)	(2,273,130)
Cash and cash equivalents at beginning of period	5,801,042	7,174,213
Cash and cash equivalents at end of period	$ 5,744,193	$ 4,901,083